Incidence, Risk Factors, and Outcome of Cytomegalovirus Viremia and Gastroenteritis in Patients with Gastrointestinal Graft-versus-host Disease

Overview

Journal Biol Blood Marrow Transplant

Date 2014 Dec 3

PMID 25445637

Citations 23

Authors

Divaya Bhutani

Gregory Dyson

Richard Manasa

Abhinav Deol

Voravit Ratanatharathorn

Lois Ayash

Muneer Abidi

Lawrence G Lum

Zaid Al-Kadhimi

Joseph P Uberti

Affiliations

Soon will be listed here.

Abstract

Gastrointestinal (GI) graft-versus-host disease (GVHD) is one of the most common causes of morbidity and mortality after allogeneic stem cell transplantation. In addition, cytomegalovirus (CMV) infection of the gastrointestinal tract can complicate the post-transplantation course of these patients and it can be difficult to differentiate the 2 diagnoses given that they can present with similar symptoms. We retrospectively analyzed 252 patients who were diagnosed with GI GVHD to evaluate the incidence, risk factors, and outcomes of CMV viremia and CMV gastroenteritis in these patients. The median age at the time of transplantation was 51 years, 35% were related donor transplantations, and 65% were unrelated donor transplantations. A total of 114 (45%) patients developed CMV viremia at a median of 34 days (range, 14 to 236 days) after transplantation. Only recipient CMV IgG serostatus was significantly associated with development of CMV viremia (P < .001). The incidence of CMV viremia with relation to donor (D) and recipient (R) CMV serostatus subgroups was as follows: D+/R+, 73%; D-/R+, 67%; D+/R-, 19%; and D-/R-, 0. A total of 31 patients were diagnosed with a biopsy-proven CMV gastroenteritis; 2 patients had evidence of CMV gastroenteritis and GVHD on the first biopsy and 29 on the second biopsy. Median time to development of CMV gastroenteritis was 52 days (range, 19 to 236 days) after transplantation. Using death as a competing risk, the cumulative incidence of CMV gastroenteritis at 1 year was 16.4%. The incidence of CMV gastroenteritis in relation to the donor/recipient serostatus was as follows: D+/R+, 22%; D-/R+, 31%; D+/R-, 12%; and D-/R-, 0. Median follow-up time for the 252 patients was 35.4 (95% CI 23.8 to 44.8) months. The estimated overall survival rate at 1 and 2 years was .45 (95% confidence interval [CI], .39 to .52) and .39 (95% CI, .33 to .46), respectively. Of the examined variables, those related to the overall survival were maximal clinical GVHD grade (P < .001) and development of CMV gastroenteritis (P = .008). Development of CMV viremia was not associated with increased mortality. In conclusion, CMV gastroenteritis is common complication in patients with GI GVHD and can adversely affect the prognosis.

Citing Articles

[Role of human herpesvirus infection in refractory gastrointestinal graft-versus-host-disease after hematopoietic stem cell transplantation and the diagnosis and treatment thereof].

He H, Zhang J, Wei Z, Lu Y, Zhao Y, Sun R Zhonghua Xue Ye Xue Za Zhi. 2025; 45(11):1016-1021.

PMID: 39746695 PMC: 11886680. DOI: 10.3760/cma.j.cn121090-20240906-00339.

Long-Term Follow Up of Patients Treated for Inflammatory Bowel Disease and Cytomegalovirus Colitis.

Singh G, Rentsch C, Beattie W, Christensen B, Macrae F, Segal J Diagnostics (Basel). 2024; 14(18).

PMID: 39335709 PMC: 11431378. DOI: 10.3390/diagnostics14182030.

Letermovir Primary Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: Real-Life Data from a University Hospital in Argentina.

Herrera F, Torres D, Querci M, Rearte A, Temporiti E, Riera L Mediterr J Hematol Infect Dis. 2024; 16(1):e2024039.

PMID: 38882462 PMC: 11178052. DOI: 10.4084/MJHID.2024.039.

Late cytomegalovirus disease after hematopoietic cell transplantation: significance of novel transplantation techniques.

Sadowska-Klasa A, Ozkok S, Xie H, Leisenring W, Zamora D, Seo S Blood Adv. 2024; 8(14):3639-3651.

PMID: 38537062 PMC: 11284709. DOI: 10.1182/bloodadvances.2023012175.

Development of an explainable AI system using routine clinical parameters for rapid differentiation of inflammatory conditions.

Hoffmann J, Rheude A, Neubauer A, Brendel C, Thrun M Front Immunol. 2024; 15:1364954.

PMID: 38510238 PMC: 10950914. DOI: 10.3389/fimmu.2024.1364954.

References

Qamruddin A, Oppenheim B, Guiver M, Mutton K, Chopra R . Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection. Bone Marrow Transplant. 2001; 27(3):301-6. DOI: 10.1038/sj.bmt.1702778. View

Cho B, Yahng S, Kim J, Yoon J, Shin S, Lee S . Impact of cytomegalovirus gastrointestinal disease on the clinical outcomes in patients with gastrointestinal graft-versus-host disease in the era of preemptive therapy. Ann Hematol. 2012; 92(4):497-504. DOI: 10.1007/s00277-012-1632-x. View

MacMillan M, Weisdorf D, Wagner J, DeFor T, Burns L, Ramsay N . Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant. 2002; 8(7):387-94. DOI: 10.1053/bbmt.2002.v8.pm12171485. View

Boeckh M, Leisenring W, Riddell S, Bowden R, Huang M, Myerson D . Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2002; 101(2):407-14. DOI: 10.1182/blood-2002-03-0993. View

Hakki M, Riddell S, Storek J, Carter R, Stevens-Ayers T, Sudour P . Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood. 2003; 102(8):3060-7. DOI: 10.1182/blood-2002-11-3472. View

Mori T, Mori S, Kanda Y, Yakushiji K, Mineishi S, Takaue Y . Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003; 33(4):431-4. DOI: 10.1038/sj.bmt.1704369. View

Couriel D, Caldera H, Champlin R, Komanduri K . Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer. 2004; 101(9):1936-46. DOI: 10.1002/cncr.20613. View

Meyers J, Flournoy N, Thomas E . Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986; 153(3):478-88. DOI: 10.1093/infdis/153.3.478. View

Bowden R, Sayers M, Flournoy N, Newton B, Banaji M, Thomas E . Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986; 314(16):1006-10. DOI: 10.1056/NEJM198604173141602. View

10.

Winston D, Ho W, Lin C, Bartoni K, Budinger M, Gale R . Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med. 1987; 106(1):12-8. DOI: 10.7326/0003-4819-106-1-12. View

11.

Meyers J, Reed E, Shepp D, Thornquist M, Dandliker P, Vicary C . Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med. 1988; 318(2):70-5. DOI: 10.1056/NEJM198801143180202. View

12.

Wingard J, Chen D, BURNS W, Fuller D, Braine H, Yeager A . Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood. 1988; 71(5):1432-7. View

13.

Schmidt G, Kovacs A, Zaia J, Horak D, Blume K, Nademanee A . Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation. 1988; 46(6):905-7. View

14.

Martin P, Schoch G, Fisher L, BYERS V, Anasetti C, Appelbaum F . A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990; 76(8):1464-72. View

15.

MILLER W, McCullough J, Balfour Jr H, Haake R, Ramsay N, Goldman A . Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant. 1991; 7(3):227-34. View

16.

Goodrich J, Mori M, Gleaves C, Du Mond C, Cays M, Ebeling D . Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991; 325(23):1601-7. DOI: 10.1056/NEJM199112053252303. View

17.

Einsele H, Ehninger G, Hebart H, Wittkowski K, Schuler U, Jahn G . Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995; 86(7):2815-20. View

18.

Boeckh M, Gooley T, Myerson D, Cunningham T, Schoch G, Bowden R . Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996; 88(10):4063-71. View

19.

Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard J, Lee S . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12):945-56. DOI: 10.1016/j.bbmt.2005.09.004. View

20.

Ljungman P, Perez-Bercoff L, Jonsson J, Avetisyan G, Sparrelid E, Aschan J . Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006; 91(1):78-83. View